Cargando...
RAS-MAPK in ALK targeted therapy resistance
The clinical success of ALK targeted therapy is limited by resistance. To identify rational co-targeting strategies to enhance clinical outcomes, we explored the molecular basis of ALK oncogene dependence in ALK gene rearrangement positive (ALK+) lung adenocarcinoma. We discovered that the RAS-RAF-M...
Guardado en:
| Publicado en: | Cell Cycle |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Taylor & Francis
2015
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4825705/ https://ncbi.nlm.nih.gov/pubmed/26654768 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2015.1096103 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|